{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/trigeminal-neuralgia/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"064b944d-9f86-5ad2-bdde-418e427a69cf","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field ca34a12d-21da-4dee-ac3c-bc9ec9a2a70f --><h2>Changes</h2><!-- end field ca34a12d-21da-4dee-ac3c-bc9ec9a2a70f -->","summary":null,"htmlStringContent":"<!-- begin item 2000585d-b273-4a72-a211-95bff922045f --><!-- begin field 42cb6815-b27c-4980-8c0e-3d7606679e76 --><p><strong>January 2018</strong> — minor update. Revised SPC for Tegretol (carbamazepine) - all formulations, information regarding drug interactions updated as per revised SPC.  </p><p><strong>February to March 2017 </strong>— reviewed. A literature search was conducted in February 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic has undergone restructuring. No major changes to the recommendations have been made.</p><!-- end field 42cb6815-b27c-4980-8c0e-3d7606679e76 --><!-- end item 2000585d-b273-4a72-a211-95bff922045f -->","topic":{"id":"b411a210-e8ef-56d4-8840-714bb3ca8b7d","topicId":"dd0f36c2-b31b-42ca-bc80-17ddb7e243ec","topicName":"Trigeminal neuralgia","slug":"trigeminal-neuralgia","lastRevised":"Last revised in January 2018","chapters":[{"id":"5a46b0ae-84bb-5e91-9f06-d82e7de90660","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6ebb1131-0f9c-5613-9b6d-c44044dc3d59","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"04895c32-0679-538d-bd7f-566f3b1aca33","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"064b944d-9f86-5ad2-bdde-418e427a69cf","slug":"changes","fullItemName":"Changes"},{"id":"215b2ed2-a6ff-5053-b74a-72ca907fbb6f","slug":"update","fullItemName":"Update"}]},{"id":"0d57219c-f171-59f5-b932-8cabc9dd5049","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d78c8e6b-affd-55c5-8e55-1db5bbe57261","slug":"goals","fullItemName":"Goals"},{"id":"135b5ce1-adf5-5fa9-8d6a-a90e64183628","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2dd53a4e-0dcf-5797-90d1-ac0ae3a56a93","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"a8fd6b61-b1c3-538d-b032-872f1d3427c2","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7d867bfa-0e88-5dbe-85c4-50f28d24c9c8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"38f48973-5497-53e5-a936-4b59cbd4b662","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ff1b2d66-75ed-51c6-bfa9-fcc0ad6d6bac","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"2e9fdd75-4a7e-56ad-8c9d-02ac90da26bd","slug":"definition","fullItemName":"Definition"},{"id":"4dc2aba7-3510-51d4-9aab-2596d348bd1a","slug":"causes","fullItemName":"Causes"},{"id":"6e2bbd60-dabb-5cdb-86d0-29bd0a23615b","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"7c45985c-eb6e-5f96-9d9b-44cc50b51476","slug":"prevalence","fullItemName":"Prevalence"},{"id":"16848fcb-77c6-5043-9c84-eadffb6ff3aa","slug":"prognosis","fullItemName":"Prognosis"},{"id":"a7f1ea99-b3b5-5e53-952d-515327e12d83","slug":"complications","fullItemName":"Complications"}]},{"id":"5c22d7af-254a-51f1-a8b9-07efa299f48b","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"bbf28df3-9b64-5c32-85b5-26dc3c2cc0af","slug":"diagnosis","fullItemName":"Diagnosis"}]},{"id":"feea47e1-4766-5814-8cd9-3adf7df4600f","fullItemName":"Management","slug":"management","subChapters":[{"id":"5008bdc5-02f7-558d-9c72-fa0bd4f2c01a","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"ff7b11db-4087-5134-804a-f231a32cf2ce","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"74b691ce-0764-54e6-a932-11f0755c3089","slug":"carbamazepine","fullItemName":"Carbamazepine"}]},{"id":"ae57d488-a470-558c-b5d7-81fb47f8fbad","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"90e907d0-34e8-53cc-a9f6-53b0de5c633c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c39bcb69-119d-5f65-927c-00c82813d6f3","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"614a98b5-320e-5735-b0f4-c72808b83068","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"4c55bb70-6e39-5673-898f-4244d6e219e7","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"5b8a3490-a3c6-565b-9f06-fc347a6c2eb4","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"12e3df2a-fa39-57fa-b4ef-e222cd41fa5b","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d1abb506-cecf-562c-84a9-1e2167e7129f","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"04895c32-0679-538d-bd7f-566f3b1aca33","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"ff4828f2-1d53-51cd-bd49-6b268431bdcf","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field ab2f9b52-02ef-46f5-86cc-95dfb46113a1 --><h3>Previous changes</h3><!-- end field ab2f9b52-02ef-46f5-86cc-95dfb46113a1 -->","summary":null,"htmlStringContent":"<!-- begin item 873487a7-bfdb-4dca-b425-9f6c6e9e0b41 --><!-- begin field 219674ed-b667-416e-b89c-d19dfbe00664 --><p><strong>December 2016</strong> — minor update. Information that carbamzepine levels may be increased when taken concomitantly with antivirals, such as ritonavir, has been added to the drug interactions section of this topic, in line with the manufacturer's Summary of Product Characteristics.</p><p><strong>December 2014 </strong>—<strong> </strong>minor update. Minor typographical error corrected.</p><p><strong>March 2014 </strong>—<strong> </strong>minor update. The recommendation to consider gabapentin if carbamazepine is inappropriate, ineffective, or not tolerated has been changed in line with the updated NICE guideline on pharmacological treatment of neuropathic pain. Specialist advice or referral is now recommended in this case.</p><p><strong>January 2014 </strong>— minor update. Minor text changes to reflect the updated Summary of Product Characteristics for carbamazepine tablets regarding the maximum recommended daily dose for management of trigeminal neuralgia and minor typographical error corrected.</p><p><strong>October 2012 to February 2013 </strong>— reviewed. A literature search was conducted in September 2012 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of this topic. Pregabalin has been added to the treatment options.</p><p><strong>September 2010 </strong>— minor update. A <em>Prescribing information</em> section has been included in this topic. Issued in September 2010.</p><p><strong>June to November 2008 </strong>— converted from CKS guidance to CKS topic structure. The evidence base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. There have been no major changes to the recommendations.</p><p><strong>April 2008 </strong>— minor update. Update to the text in medicines management to reflect recent MHRA advice regarding genetic testing for carbamazepine. Issued May 2008.</p><p><strong>July 2007 </strong>— minor update. Clarification of when to refer for an MRI head scan to exclude a structural cause has been included. Issued in August 2007.</p><p><strong>June 2007 </strong>— minor update. Gabapentin is now licensed up to a maximum dose of 3600 mg per day for the treatment of peripheral neuropathic pain. Issued in June 2007.</p><p><strong>January 2007 </strong>— typographical error corrected. Issued in January 2007.</p><p><strong>October 2005 </strong>— minor technical update. Issued in November 2005.</p><p><strong>March 2005 </strong>— reviewed. Validated in June 2005 and issued in July 2005.</p><p><strong>January 2002 </strong>— reviewed. Validated in March 2002 and issued in April 2002.</p><p><strong>October 1998 </strong>— written. Validated in November 1998 and issued in December 1998.</p><!-- end field 219674ed-b667-416e-b89c-d19dfbe00664 --><!-- end item 873487a7-bfdb-4dca-b425-9f6c6e9e0b41 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}